Two Sigma Investments
IKT icon

Two Sigma Investments’s Inhibikase Therapeutics IKT Stock Holding History

Two Sigma Investments’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Buy
+847,611
New +$1.51M ﹤0.01% 3006
2022
Q1 		– Sell
-1,917
Closed -$17K – 3429
2021
Q4 		$17K Buy
+1,917
New +$21.2K ﹤0.01% 4178

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments's IKT Position: Q1 2026 in Review

Two Sigma Investments opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 847,611 shares worth $1.42M. The stake represents ﹤0.01% of the portfolio and ranks #3006 among its holdings. This is a return to the name: Two Sigma Investments previously reported a position in IKT as recently as Q4 2021.

Two Sigma Investments first reported a position in IKT in Q4 2021 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Two Sigma Investments held 847,611 shares of Inhibikase Therapeutics worth $1.42M as of Q1 2026.
  • Inhibikase Therapeutics was a new Two Sigma Investments position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3006 holding.
  • Two Sigma Investments first reported a position in Inhibikase Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.